- Combination Treatment Safety: Patients with metastatic castration-resistant prostate cancer (mCRPC) who received both external beam radiation therapy (EBRT) and radium-223 (Ra-223) did not show an increased risk of blood-related issues compared to those who did not undergo prior EBRT.
- Hematological Side Effects: The occurrence of drug-related hematological side effects was similar between patients treated with EBRT and those who did not receive EBRT. Severe or worse side effects were also comparable between the two groups.
- Treatment Discontinuations and Deaths: A small percentage of patients in both the EBRT and non-EBRT groups discontinued Ra-223 treatment due to side effects, and side effects resulting in death were reported in one patient from each group.
- Bone Fractures and Second Primary Malignancies: The incidence of bone fractures was slightly higher in the EBRT group compared to the non-EBRT group. Additionally, the overall occurrence of second primary malignancies (SPMs) remained low, with no blood-related cancers reported in the study.